Relugolix combination therapy in European women with symptomatic uterine fibroids: a subgroup analysis from the randomized phase 3 LIBERTY pivotal trials

• Ngā kaituhi matua: Roberta Venturella (Author), Tomasz Rechberger (Author), János Zatik (Author), Rachel B. Wagman (Author), Emily Zhu (Author), Viatcheslav G. Rakov (Author), Felice Petraglia (Author)
• Hōputu: Pukapuka
• I whakaputaina: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Objective In the 24-week, phase 3 LIBERTY 1 (L1) and LIBERTY 2 (L2) trials, relugolix combination therapy (relugolix-CT (relugolix 40 mg, estradiol 1 mg, norethisterone acetate 0.5 mg)) reduced uterine fibroid (UF)-associated symptoms. This post hoc analysis assessed safety and efficacy of relugolix...